Table 3. Clinical variables associated with infections post CD19 CAR-T cell therapy for NHL.

	Non-infection (N=10)	Infection (N=9)	P value
CRS, n (%)	7 (70.0)	5 (55.5)	0.52 (chi square) 0.65 (Fisher’s exact)
ICANS, n (%)	9 (90.0)	5 (55.6)	0.089 (chi square) 0.141 (Fisher’s exact)
Median ANC (D30)	1.55 (0.8–1.9)	0.8 (0.7–1.1)	0.29 (KW)
Median AMC (D30)	0.4 (0.3–0.5)	0.3 (0.3–0.4)	0.25 (KW)
Median ALC	0.3 (0.1–0.5)	0.5 (0.5–0.9)	0.10 (KW)
Median ANC/ALC*	3.6 (2.7–6.3)	1.2 (0.68–2.41)	0.01 (KW)
Median AMC/ALC*	1.67 (0.8–3)	0.37 (0.26–0.69)	0.012 (KW)
ANC >1,500/µL, D90, n (%)	7 (70.0)	2 (22.2)	0.11 (chi square) 0.069 (Fisher’s exact)
Median PFS	664	Not reached	0.71 (Log rank)
Responders to CAR-T	9 (90.0)	6 (66.7)	0.30 (Fisher’s exact)

The ANC, AMC, and ALC values at D30 were calculated using minimum and maximum values between D20 to D40. *The infection group had 8 people, and the non-infection group had 9 people because some patients had 0 as a minimum ALC level. CAR-T, Chimeric antigen receptor T cell; NHL, non-Hodgkin’s lymphoma; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; KW, Kruskal Wallis.